Phenacetin was the world’s first synthetic painkiller, introduced to pharmacies in 1887 and used by millions of people for nearly a century before regulators pulled it from the market. The United States withdrew it in 1983, and most other countries followed within a few years, after mounting evidence linked long-term use to severe kidney disease and cancers of the urinary tract.1ScienceDirect. Phenacetin The story of phenacetin is tangled up with the story of its replacement, acetaminophen (known as paracetamol outside North America), in ways that still matter for how we think about over-the-counter painkillers today.
A Brief Life as a Blockbuster Drug
Phenacetin was synthesized in 1878 by the American chemist Harmon Northrop Morse and reached the pharmaceutical market nine years later. It belonged to a new class of painkillers that were not derived from opium, which made it enormously attractive at a time when the main alternatives were morphine and its relatives. Unlike aspirin, which came along about a decade later, phenacetin had no anti-inflammatory effect. It worked purely as a pain reliever and fever reducer.1ScienceDirect. Phenacetin
For most of the twentieth century, phenacetin was a staple ingredient in popular compound analgesic tablets and powders, often combined with aspirin and caffeine. These combination products were sold without prescription in many countries and became part of daily life for people with chronic headaches, arthritis pain, or general aches. In some regions, particularly Australia and parts of Europe, heavy habitual use of these compound analgesics became a recognized public health problem, with the underlying issue described as behavioral and environmental rather than purely medical.2Wiley Online Library. Analgesic abuse and kidney disease
How the Body Handles Phenacetin
One of the most important things about phenacetin is that your body does not leave it intact for long. Once swallowed, phenacetin is converted in the liver primarily into acetaminophen through a chemical step called O-deethylation. In other words, phenacetin is essentially a prodrug for acetaminophen: much of its painkilling effect comes from that conversion product.3PubMed Central. Reactive metabolites of phenacetin and acetaminophen: a review The liver enzyme CYP1A2 plays a central role in this process. In mice engineered to lack CYP1A2, blood levels of phenacetin stayed higher and acetaminophen levels stayed lower compared to normal animals, confirming that this enzyme is the main driver of the conversion.4Toxicological Sciences. Role of CYP1A2 in the toxicity of long-term phenacetin feeding in mice
But the liver does not just produce acetaminophen. It also generates several other breakdown products, and some of these are toxic. Two metabolites in particular, N-hydroxyphenacetin and p-aminophenol, turned out to be directly damaging to the kidneys and to red blood cells. It is these side pathways, not the main acetaminophen pathway, that gave phenacetin its dangerous reputation.
Kidney Damage Was the Central Concern
The condition that drove phenacetin off the market was analgesic nephropathy, a form of chronic kidney disease caused by long-term painkiller use. Doctors had been describing kidney damage in heavy phenacetin users since at least the late 1950s, and by the 1970s the pattern was clear: habitual use of phenacetin-containing analgesics was strongly associated with destruction of the kidney’s inner tissue, particularly the papillae, which are the pointed structures at the core of the kidney where urine concentrates before draining into the collecting system.
The mechanism involves an unfortunate quirk of kidney anatomy. When phenacetin is converted to acetaminophen, that acetaminophen concentrates heavily in the inner medulla of the kidney during normal water conservation. Studies in animals showed that acetaminophen levels at the papillary tip could reach more than ten times the concentration found in the outer part of the kidney. Researchers concluded that papillary necrosis from phenacetin was likely related to this buildup of acetaminophen deep in the kidney’s interior.5PubMed Central. Renal accumulation of salicylate and phenacetin: possible mechanisms in the nephropathy of analgesic abuse
On top of that, the kidney itself can produce toxic metabolites from phenacetin locally. N-hydroxyphenacetin and p-aminophenol, both confirmed to be directly toxic to kidney tissue, can be formed in the kidney’s own cellular machinery, not just in the liver. When that local production was experimentally boosted, kidney damage worsened in parallel.6Journal of Pharmacobio-Dynamics. METABOLISM AND NEPHROTOXICITY OF PHENACETIN AND SULFANILAMIDE So the kidney was being hit from two directions: high concentrations of acetaminophen pooling at its most vulnerable point, and toxic byproducts being generated right there in the tissue.
Epidemiological studies across the United States and Europe found that habitual phenacetin use carried a relative risk for chronic kidney failure and end-stage renal disease in the range of 4 to 19, depending on the study and population.7PubMed. Habitual use of acetaminophen as a risk factor for chronic renal failure: a comparison with phenacetin Those are striking numbers. A relative risk of 4 means habitual users were about four times as likely to develop kidney failure as people who avoided the drug; a relative risk of 19 means they were nearly twenty times as likely. That range reflects differences in how “habitual use” was defined and how populations were studied, but even the low end of the range was alarming enough to justify a ban.
Cancer of the Urinary Tract
Kidney damage alone might have been enough to end phenacetin’s run, but the cancer evidence sealed it. Studies linked phenacetin-based analgesics to cancers of the renal pelvis (the funnel-shaped part of the kidney that collects urine), the bladder, and to a lesser extent the kidney tissue itself. A study of women found that the relative risk for cancer of the renal pelvis was about 5.4 with phenacetin use, and that using both phenacetin-containing analgesics and tobacco together produced a greater-than-additive effect. Analgesic preparations without phenacetin did not raise the risk at either site.8PubMed. Phenacetin-containing analgesics and cancer of the bladder or renal pelvis in women
Particularly telling was research that tried to separate the effects of phenacetin from those of acetaminophen. One study found that the risk of renal pelvic cancer was increased roughly twelve-fold by phenacetin-aspirin compound analgesics, while acetaminophen on its own did not significantly raise the risk for that particular cancer. The researchers proposed that phenacetin-aspirin compounds were potently cancer-causing in the renal pelvis through pathways involving papillary necrosis, above and beyond whatever acetaminophen did on its own.9PubMed. Different roles for phenacetin and paracetamol in cancer of the kidney and renal pelvis In other words, the cancer risk was not simply a consequence of the acetaminophen that phenacetin turned into; phenacetin brought something extra to the table.
Laboratory tests exploring how phenacetin might cause cancer found a complicated picture. Phenacetin was not a strong direct DNA-damaging agent in most standard tests. It showed weak activity in certain bacterial mutation assays and produced a small but statistically significant increase in chromosomal changes in mouse bone marrow cells. Some signs of DNA damage appeared in rat kidneys, though the interpretation was uncertain.10PubMed. Assay of phenacetin genotoxicity using in vitro and in vivo test systems The overall picture suggests that phenacetin’s cancer-causing potential may depend heavily on how and where the body converts it, rather than on the parent molecule being a straightforward mutagen.
Blood Disorders
A third category of harm, less discussed than kidneys and cancer but clinically important, was phenacetin’s effect on red blood cells. Phenacetin is well known to cause hemolytic anemia, a condition in which red blood cells are destroyed faster than the body can replace them, and methemoglobinemia, in which the oxygen-carrying molecule in red blood cells is chemically altered so it can no longer deliver oxygen efficiently.11PubMed. The role of N-hydroxyphenetidine in phenacetin-induced hemolytic anemia
The culprit appears to be N-hydroxyphenetidine (PNOH), a metabolite formed during phenacetin’s breakdown. In rat studies, PNOH was significantly more potent at destroying red blood cells than either phenacetin itself or its other metabolites, and it acted directly on the cells rather than requiring further chemical conversion. Clinically, doctors could spot the damage by looking at blood smears: affected red cells showed characteristic “bitten out” shapes, and specialized staining revealed Heinz bodies, clumps of damaged hemoglobin inside the cells.12PubMed Central. Phenacetin-induced hemolytic anemia For patients already taking phenacetin regularly for chronic pain, these blood abnormalities could develop insidiously over weeks or months before producing obvious symptoms like fatigue and shortness of breath.
What Replaced Phenacetin and Whether That Was Actually Safer
The obvious successor was acetaminophen. Since phenacetin was largely converted to acetaminophen in the body anyway, regulators and manufacturers reasoned that giving acetaminophen directly would skip the dangerous side metabolites while preserving the pain relief. Acetaminophen had been available since the 1950s, and after phenacetin’s withdrawal it became one of the most widely used drugs on Earth.
The assumption that acetaminophen was categorically safer than phenacetin has been described bluntly in the medical literature as a “false assumption.” Acetaminophen carries its own serious risks, most notably liver failure from the toxic metabolite NAPQI, which can accumulate after overdose or in people whose livers are already stressed by alcohol or other drugs.13PubMed. Acetaminophen/paracetamol: A history of errors, failures and false decisions And the kidney question did not disappear entirely. Three case-control studies found that habitual use of acetaminophen itself was associated with chronic kidney failure and end-stage renal disease, with a relative risk in the range of 2 to 4. That is lower than the range seen with phenacetin, but not zero.7PubMed. Habitual use of acetaminophen as a risk factor for chronic renal failure: a comparison with phenacetin
The researchers who studied this were careful to note that the apparent difference in kidney risk between phenacetin and acetaminophen might not reflect a real difference in the drugs’ potential to harm the kidneys. Differences in dose, in how the drugs were marketed (phenacetin was typically sold in combination products that encouraged higher consumption), and in who used them could all have muddied the comparison. The takeaway was not “acetaminophen is safe for kidneys” but rather “acetaminophen may be somewhat less risky than phenacetin, though the reasons are debatable.”
What Happened After the Ban
One of the clearest pieces of evidence that phenacetin was genuinely the problem, and not just a scapegoat, comes from what happened after it was removed from the market. An autopsy study in Basel, Switzerland tracked the prevalence of analgesic nephropathy over two decades. The rate dropped from roughly 3% of autopsied cases in 1980 to just 0.2% in 2000. Capillary sclerosis of the urinary tract, the early tissue change that kicks off the cascade toward papillary necrosis, fell from 4% to essentially a single case by the end of the study period. This happened despite the fact that combination analgesics containing acetaminophen (phenacetin’s main metabolite and replacement) remained popular and widely used throughout the same period.14Nephrology Dialysis Transplantation. Obituary to analgesic nephropathy—an autopsy study
A similar pattern emerged in Berlin. After phenacetin was removed from the German market in 1986, the proportion of end-stage kidney disease attributed to analgesic nephropathy fell from 30% in 1981–1982 to 12% by 1995–1997. The researchers noted some caveats: the overall number of dialysis patients was rising during the same period due to aging populations and more diabetes, so the relative decline in analgesic nephropathy had to be interpreted against a shifting background. Still, the trend was consistent with phenacetin being the primary driver of the problem.15Nephrology Dialysis Transplantation. Incidence of analgesic nephropathy in Berlin since 1983
Phenacetin’s Second Life as a Drug Cutting Agent
Phenacetin may have vanished from pharmacy shelves, but it has not vanished from the world. It is now frequently detected in seized cocaine samples as a cutting agent, meaning it is added to bulk up the product and increase profits. Forensic reviews have identified phenacetin as one of the most common adulterants found in cocaine alongside caffeine, levamisole, and lidocaine.16Forensic Science International. The cutting of cocaine and heroin: A critical review
Why phenacetin specifically? It is cheap to manufacture, it dissolves and blends well with cocaine hydrochloride, and it produces a mild numbing or analgesic sensation that may make the product seem higher quality. Forensic chemists have developed isotope-ratio techniques to trace the origin of phenacetin found in seizures, since the drug’s legitimate pharmaceutical production has largely ceased and its presence in a sample is itself a red flag.17PubMed. IRMS to study a common cocaine cutting agent: phenacetin For people who use cocaine regularly, this means inadvertent chronic exposure to a substance banned precisely because of its kidney-damaging and cancer-causing potential. It is one of those grim ironies: the drug was removed from legal pain relievers to protect public health, and it resurfaced in an entirely unregulated market where the risks cannot even be communicated to the people exposed.
Traces in Wastewater
Phenacetin also turns up in municipal wastewater, likely as a consequence of illicit drug use and possibly residual old pharmaceutical stocks. A study examining the presence and removal of pharmaceuticals in wastewater treatment found that phenacetin, like acetaminophen, was almost completely removed during standard treatment, returning greater than 99% removal rates and posing no measurable environmental risk at the concentrations detected.18Oxford Academic (Environmental Toxicology and Chemistry). Presence, removal, and risks of psychopharmaceuticals in wastewater streams That is actually good news from an environmental perspective: while phenacetin is still entering the water supply in small amounts, conventional sewage treatment handles it effectively. The concern is not for aquatic ecosystems but for the people ingesting it directly through adulterated drugs, where the doses are far higher and no treatment plant intervenes.
Why the Ban Took So Long
With the benefit of hindsight, it seems obvious that phenacetin should have been pulled sooner. Reports of kidney damage in heavy users were appearing in the medical literature by the late 1950s, yet the drug was not withdrawn in the United States until 1983 and in Germany until 1986. Several factors contributed to the delay. The kidney damage was mostly seen in “abusers,” people taking large quantities of compound analgesics daily for years, and it was easy to frame the problem as one of misuse rather than an inherent property of the drug. The combination products also made it difficult to pin the blame on phenacetin specifically, since aspirin and caffeine were along for the ride. And the sheer commercial popularity of phenacetin-containing products created inertia.
There is also the complicating factor that the relationship between dose, duration, and harm was not linear in a way that made individual risk easy to predict. Some heavy users developed kidney failure; others did not. Some developed urinary tract cancers; most did not. The stochastic nature of the risk, combined with the drug’s genuine usefulness as a painkiller, allowed decades of debate before regulators acted. The eventual decision was driven not by a single dramatic study but by a slow accumulation of epidemiological evidence, animal toxicology, and the availability of acetaminophen as a ready substitute that preserved the therapeutic benefit while apparently reducing (though not eliminating) the worst harms.
The phenacetin story is sometimes held up as a cautionary example in pharmacology: a drug that was genuinely effective, widely loved by patients, and commercially successful, but whose long-term risks were severe enough that its net contribution to public health turned negative. The decades it took to act on the evidence are part of the lesson, and so is the uncomfortable postscript that its replacement turned out to carry its own set of serious risks, particularly liver toxicity, that were not fully appreciated at the time of the switch.